To assess the clinical features and outcomes of SARS-CoV-2 infection among individuals with chronic HBV, emphasizing the exploration of HBV-specific outcomes and the impact of SARS-CoV-2 vaccination and variants on these outcomes.
Key Findings:
Individuals with HBV/SARS-CoV-2 had higher odds of ICU admissions (OR, 1.18; 95% CI, 1.02–1.36) and mortality at 30 days (OR, 1.22; 95% CI, 1.01–1.41) and overall (OR, 1.18; 95% CI, 1.06–1.33).
Those with HBV/SARS-CoV-2 and cirrhosis had 2.0- to 2.50-fold higher odds of adverse outcomes.
Vaccinated individuals with HBV/SARS-CoV-2 had significant reductions in mortality (30-day: 57%, 90-day: 54%, overall: 29%).
The pre-Delta variant period was associated with higher hospitalization odds compared to the Omicron variant.
Interpretation:
Chronic HBV infection is associated with worse outcomes in SARS-CoV-2 infection, while vaccination significantly mitigates mortality risks, highlighting the need for targeted clinical strategies.
Limitations:
The study may not account for all confounding factors influencing outcomes, such as specific comorbidities.
Data is limited to a specific geographic region and may not be generalizable.
